Evidence map›Paper›PMID 39352380›Full record

ReviewThe Journal of clinical investigation2024

Distinct landscape and clinical implications of therapy-related clonal hematopoiesis.

Koichi Takahashi, Daisuke Nakada, Margaret Goodell

Abstract readReview
In one paragraph

Review in The Journal of clinical investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Pandora's Box of AML: HowBiomedicines · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Koichi TakahashiDepartments of Leukemia and Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Daisuke NakadaDepartment of Molecular and Human Genetics and.
Margaret GoodellDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Project 3: Contribution of inflammation and DNA damaging factors to clonal expansion and malignant transformation in a community cohort of older adultsP01CA265748 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Koichi Takahashi · 2022 to 2026
$13.6M
PPM1D in Clonal Hematopoiesis and MalignanciesR01CA237291 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MARGARET A. GOODELL, Koichi Takahashi · 2019 to 2026
$3.7M
NCI NIH HHS P01 CA265748NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA237291
6 · The paper itself

Abstract

Therapy-related clonal hematopoiesis (t-CH) is defined as clonal hematopoiesis detected in individuals previously treated with chemotherapy and/or radiation therapy. With the increased use of genetic analysis in oncological care, the detection of t-CH among cancer patients is becoming increasingly common. t-CH arises through the selective bottleneck imposed by chemotherapies and potentially through direct mutagenesis from chemotherapies, resulting in a distinct mutational landscape enriched with mutations in DNA damage-response pathway genes such as TP53, PPM1D, and CHEK2. Emerging evidence sheds light on the mechanisms of t-CH development and potential strategies to mitigate its emergence. Due to its unique characteristics that predominantly affect cancer patients, t-CH has clinical implications distinct from those of CH in the general population. This Review discusses the potential mechanisms of t-CH development, its mutational landscape, mutant-drug relationships, and its clinical significance. We highlight the distinct nature of t-CH and call for intensified research in this field.

Indexed as

Clonal HematopoiesisMutationNeoplasmsCheckpoint Kinase 2HumansNeoplasm ProteinsProtein Phosphatase 2CTumor Suppressor Protein p53Checkpoint Kinase 2CHEK2 protein, humanNeoplasm ProteinsPPM1D protein, humanProtein Phosphatase 2CTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID39352380
PMCPMC11444158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.